Author

D. Bowtell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Assay:DNA methylation· 2

Frequent Co-Authors

A. DeFazio· 3 shared E. Lieschke· 2 shared N. Traficante· 2 shared O. Kondrashova· 2 shared O. McNally· 2 shared A. Biankin· 1 shared A. Dobrovic· 1 shared A. Llop-Guevara· 1 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. DeFazio

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Cell-autonomous BMP signalling plays a key role in the maintenance of tumour cell EMT and migration programs in human ovarian carcinoma

G. Joun, F. Zolghadr, P. Chakraborty, L. L. Thi Yen, J. J.H. Chong, D. Bowtell, A. DeFazio, M. K. Jolly, N. Seyedasli

This study investigates the role of BMP signaling in maintaining EMT and migration in ovarian cancer cells, showing that inhibiting BMP reduces EMT and migration.

bioRxiv · Apr 30, 2023 · PreprintCancer Biology

Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma

K. Nesic, O. Kondrashova, R. M. Hurley, C. McGehee, C. J. Vandenberg, G.-Y. Ho, E. Lieschke, G. Dall, N. Bound, K. Shield-Artin, M. R. Radke, A. Musafer, Z. Qing Chai, M. R. Eftekhariyan Ghamsari, M. I. Harrell, , C. L. Scott

This study shows that loss of RAD51C promoter methylation leads to PARP inhibitor resistance in high-grade serous ovarian carcinoma, independent of BRCA1 methylation status.

bioRxiv · Dec 10, 2020Cancer Biology

Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy

G. Y. Ho, E. Kyran, J. Bedo, M. Wakefield, D. Ennis, H. Mirza, S. Cooke, E. Lieschke, C. Vandenberg, O. Kondrashova, R. Upstill-Goddard, U.-M. Bailey, S. Biankin, P. Roxburgh, R. Glasspool, , H. Barker

This study identifies N-MYC pathway activation and susceptibility to EMT-targeting therapy in ovarian carcinosarcoma using genomic and pre-clinical models.

bioRxiv · Nov 24, 2020 · PreprintCancer Biology

Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors

D. Aziz, N. Portman, K. Fernandez, C. Lee, S. Alexandrou, A. Llop-Guevara, A. Yong, A. Wilkinson, C. M. Sergio, D. Ferraro, D. Etemadmoghadam, D. Bowtell, k. Investigators, V. Serra, P. Waring, , C. E. Caldon

The paper identifies cyclin E1 stabilization in BRCA1-mutated breast cancers and shows synergy between CDK2 and PARP inhibitors in treating these cancers.

bioRxiv · Jan 29, 2020Cancer Biology

Mechanisms of Chromosomal Instability in High-grade Serous Ovarian Carcinoma.

N. Tamura, N. Shaikh, D. Muliaditan, J. McGuinness, D. Moralli, M.-A. Durin, C. Green, D. Bowtell, F. Balkwill, K. Curtius, S. McClelland

This study identifies multiple co-existing mechanisms driving chromosomal instability in high-grade serous ovarian carcinoma using functional assays and cell line models.

bioRxiv · Aug 6, 2019Cancer Biology